Silexion receives Nasdaq delisting notice for equity shortfall; plans appeal

Silexion Therapeutics Corp

Nasdaq delisting notice received Aug 18, 2026 for failure to meet $2.5M shareholders' equity requirement (Rule 5550(b)(1)).
Shareholders' equity as of June 30, 2026 was only $44,000, far below required minimum.
Company intends to appeal by Aug 25, 2026; under Mandatory Hearings Panel Monitor limiting compliance extensions.
If appeal fails, ordinary shares and warrants (SLXN, SLXNW) will be suspended and delisted via Form 25-NSE.

Featured in Daily 8-K Digest

Selected #1 for 2026-08-21. Read digest

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.